Zelboraf for metastatic melanoma approved by FDA

  Ordering Zelboraf   On Wednesday, August 17, the Food and Drug Administration approved Zelboraf, a drug for BRAF V600E mutation-positive metastatic melanoma. Along with skin cancer drug, FDA approved Companion Diagnostic, a mutation diagnostic test. “Today’s approval of Zelboraf and the (companion) test is a great example of how companion diagnostics can be developed [...]